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Objectives: In this study, we examined the possibility of using targeted antibodies and
the potential of small molecular therapeutics (acetylcholine, nicotine and tacrine) to block
the pro-inflammatory and adhesion-related properties of monomeric C-reactive protein
(mCRP).
Methods: We used three established models (platelet aggregation assay, endothelial
leucocyte binding assay and monocyte inflammation via ELISA and Western blotting) to
assess the potential of these therapeutics.
Results: The results of this study showed that monocyte induced inflammation (raised
tumor necrosis factor-alpha-TNF-α) induced by mCRP was significantly blocked in the
presence of acetylcholine and nicotine, whilst tacrine and targeted antibodies (clones
8C10 and 3H12) had less of or no significant effects. Western blotting confirmed
the ability of acetylcholine to inhibit mCRP-induced cell signaling phosphorylation of
extracellular signal regulated kinase 1/2 (ERK1/2), p38 and nuclear factor-kappa B
(NF-κB). There was no evidence of direct binding between small molecules and mCRP.
mCRP also induced endothelial cell-monocyte adhesion in a dose dependent fashion,
however, both acetylcholine and nicotine as well as targeting antibodies notably inhibited
adhesion. Finally, we investigated their effects on mCRP-induced platelet aggregation.
All three small molecules significantly attenuated platelet aggregation as did the antibody
8C10, although 3H12 had a weaker effect.
Discussion: Acetylcholine and to a lesser extent nicotine show potential for therapeutic
inhibition of mCRP-induced inflammation and cell and platelet adhesion. These results
highlight the potential of targeted antibodies and small molecule therapeutics to inhibit
the binding of mCRP by prevention of membrane interaction and subsequent activation
of cellular cascade systems, which produce the pro-inflammatory effects associated with
mCRP.
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INTRODUCTION
Activated platelets and endothelial leucocyte interactions
represent an important link between pro-thrombotic and
pro-inflammatory association of monomeric C-reactive protein
(mCRP). These interactions may play a significant role in
atherogenesis of cardiovascular diseases leading to acute
ischemic stroke and a more chronic role in the development of
brain lesions in vascular dementia and associated diseases (1).
It has been shown that cell membranes, liposomes, and
static activated platelets can dissociate pentameric or native
C-reactive protein (nCRP) into the monomeric and highly
pro-inflammatory form via binding to phosphocholine groups
on lysophosphatidylcholine. The main proposed mechanism
of mCRP-associated interaction with cellular membranes and
receptors is via its cholesterol binding domain (cystathionine-β-
synthase; CBS; a.a 35–47). In this mechanism, the hydrophobic
region of the mCRP inserts into lipid rafts of the plasma
membrane binding to cholesterol molecules (2). Similarly,
deposition of mCRP on to endothelial cell (EC)-circulating micro
particles seems to be associated with chronic inflammation and
linked to macrophage activation and T cell polarization (3).
Recently, Thiele et al. (4) described a phospholipase-
A2 blocking mechanism using 2-(p-amylcinnamoyl)-amino-4-
chlorobenzoic acid, (ONO-RS) that effectively prevented nCRP
association with lysophosphatidylcholine on the cell surface and
subsequent dissociation to mCRP concomitantly, significantly
attenuating the pro-inflammatory effects of the protein both in
vitro and in vivo. This work suggested that effective blocking
of the binding of mCRP to the cell membrane could inhibit
dissociation and abrogate the detrimental effects known to
be associated with neurological inflammation and subsequent
stroke worsening and/or dementia, as well as cardiovascular
instability and complication (5). However currently considered
anti-inflammatory molecules such as interleukin-1 receptor (IL-
1R) antagonist may not be effective therapeutic agents being
difficult to pass through the blood-brain-barrier (6) and/or
having possible toxic and off pathway side-effects when given
systemically at doses that could be useful therapeutically (7).
Given the structural similarity between phosphocholine and
acetylcholine we became interested in examining the potential
of this neurotransmitter and two representative cholinergic small
molecules, nicotine and tacrine, to perturb the actions of mCRP.
Here, we investigated the potential of a number of compounds
anticipated to interact with mCRP/phosphatidylcholine in
an effort to understand their capability and, subsequently,
mechanism of action in blocking mCRP-mediated
inflammation, EC-monocyte activation and platelet
aggregation.
MATERIALS AND METHODS
Cell Culture and Differentiation
U937 cells were maintained in RPMI 1640 medium
supplemented with 10% de-complemented Fetal Bovine
Serum (FBS) under humidified 5% CO2 air at 37
◦C in a T-75
flask. The media was changed every 3 days. Cell viability was
estimated using a Biorad TC1 automatic cell counter. Cell
viability was maintained above 90% for the experiment. To
induce monocyte differentiation into adherent macrophages,
the U937 cells were seeded at an initial density of 2 × 106 in
2ml of differential media/well [growth media with phorbol-
12-myristate 13-acetate (PMA) at 50 ng/ml for 72 h in a 6-well
plate]. Following differentiation, the cells were washed twice
with warm Dulbecco’s Phosphate Buffered Saline (DPBS).
Next, the macrophages were starved in RPMI 1640 medium
supplemented with 2% FBS under humidified 5% CO2 air at
37◦C for at least 24 h. Next, the macrophages were stimulated for
8min with mCRP (for Western blotting based on our previously
published observations) and 24 h for inflammation assays
following 2 h pre-incubation with acetylcholine (10–100µM),
nicotine (0.93µM) or tacrine (1µM). Concentrations of small
molecules were chosen based on published literature showing
their use as inhibitors in macrophages/glia, [acetylcholine, (8)];
[nicotine, (9)]; [tacrine, (10)] and our own pilot observations
and optimization (toxicity assay assessment of viability using
a range of concentrations for the three molecules showed that
the concentrations above were non-toxic to the U937 cells).
For the monocyte-EC adhesion assay, immortalized human
brain microvascular EC cells (HbMEC), were kindly donated
by Prof. Babette Weksler (Division of Hematology and Medical
Oncology, Weill Medical College, Cornell University, New
York). Cells were cultured routinely before use in microvascular
EC medium-2 (EBM-2) from Clonetics (Lonza, Germany),
supplemented with growth factors as recommended by the
manufacturer.
ELISA Assay
Human promonocytic leukemia U937 cells were grown in
RPMI 1640 medium supplemented with 10% FBS, (Sigma-
Aldrich) in a humidified incubator with 5% CO2 at 37
◦C. U937
monocytes (2 × 106 cells/well) were fully differentiated into
macrophages after 72 h incubation with 50 ng/ml phorbol-
12-myristate 13-acetate (PMA) in 6-well culture plates.
After washing twice with DPBS, macrophages were pre-
treated with acetylcholine (10µM), nicotine (0.93µM),
tacrine (5µM), methyllycaconitine (10µM), anti-CD16/32/64
(1:100), anti-mCRP antibody 3H12 clone (1:10), or anti-
mCRP antibody 8C10 clone (1:10) for 2 h, followed by
stimulation with mCRP (100µg/mL) for an additional 24 h.
Mouse monoclonal antibodies to human mCRP sub-unit
(8C10/3H12) were obtained from Dr L.A. Potempa and fully
characterized as described previously (11). We have previously
shown that 8C10 (N-terminal aa-22-45) pre-incubation of
EC was sufficient to block angiogenesis and associated cell
signaling (12). Here, we employed the use of this antibody
and a second similar one (3H12; C-terminal aa-198-206)
as “potential” blocking antibodies in U937 inflammatory
response.
The production of tumor necrosis factor alpha (TNF-α), IL-
6, and IL-10 in the supernatant was quantified using ELISA
kits (R&D Systems) according to the manufacturer’s instruction.
Stimulation with lipopolysaccharide (LPS) (10 ng/mL) for 24 h
was used as the positive control for macrophage cytokine
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production. Samples were tested in triplicate and results are
presented as the mean ± SD from a representative example of
three independent experiments, unless specified otherwise in the
text. ∗P ≤ 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 using ANOVA.
Western-Blot Protocol
A general RIPA buffer containing a protease and phosphatase
inhibitor cocktail was used to make the cell lysates. Following
this, the cell lysates were sonicated for 20 s and centrifuged for
10min at 10000 RFC at 4◦C. The supernatant protein samples
were collected and the protein concentrations were estimated
using the BCA protein assay. Then, the samples were frozen at
−80◦C for later use.
Equal quantities of proteins (30 µg) were mixed with 2×
Laemmli sample buffer, boiled in a water bath for 15min
and then centrifuged. Samples were separated along with
pre-stained molecular weight markers (32,000–200,000 kDa)
by 12% SDS-PAGE. Proteins were electro-transferred (Hoefer,
Bucks, UK) onto nitrocellulose filters (1 h) (Whatman, Protran
BA85, Germany) and the filters were blocked for 1 h at room
temperature in TBS-Tween (pH 7.4) containing 1% bovine serum
albumin (BSA). Filters were then stained with the primary
antibodies diluted in the blocking buffer, overnight at 4◦C
on a rotating shaker. The following primary antibodies were
applied at 1:1,000 dilution: phospho/total-extracellular signal-
regulated kinase 1/2 (ERK1/2) (thr202-tyr204; mab/4370 and
mab/4695, respectively; from Cell Signaling Antibodies, Bio-rad,
Hertfordshire, UK); phospho/total-jun N-terminal kinase 1/2
(JNK1/2) (t183, y185, mab/1205 and mab ab179461, respectively;
from Bio-Techne Ltd., Minneapolis, USA); phospho/total-p38
(t180, y182 ab4822, and ab27986, respectively; fromAbcam,West
Sussex, UK); and phospho/total-nuclear factor kappa B (NFκb)
(p65, S529 and p65, ab16502; from Abcam, West Sussex, UK).
After washing (5 × 10min in TBS-Tween at room
temperature), filters were stained with either goat anti-rabbit or
rabbit anti-mouse HRP-conjugated secondary antibodies diluted
in TBS-Tween containing 5% de-fatted milk (1:2,000, 1 h, room
temperature) with continuous mixing. After a further five
washes in TBS-tween, proteins were visualized using enhanced
chemiluminescence detection (ECL, Thermo Scientific, UK), and
semi-quantitatively identified fold differences compared with
house-keeping controls (α-tubulin, ab7291, Abcam,West Sussex,
UK) were determined using Image-Lab software (Bio-rad, UK).
All experiments were repeated three times and a representative
example is shown.
NF-κB Translocation Assay
Macrophages were cultured alone or in the presence of LPS
(10µg/ml) as a positive control or mCRP (100µg/ml) with and
without small molecules (2 h pre-incubation as described above)
on glass coverslips for 1 h prior to a 5min wash in PBS. Samples
were fixed in 100% methanol at−20◦C for 5min and following
evaporation, stored at−80◦C.
Prior to staining, cells were rehydrated with 0.05% PBST.
Non-specific binding of the secondary antibody was blocked
using 4% goat serum (Vector laboratories, Peterborough, UK) for
30min. Cells were washed with PBST (2× 5min) then incubated
overnight with NF-κB p65 rabbit mAb 16502 (Cell Signaling,
MA, USA) at 1:400 dilution. Cells were then rinsed twice
with PBST for 5min, and incubated with goat anti-rabbit IgG
secondary antibody (Alexa Fluor 488; Thermo-Fisher scientific,
Runcorn, UK) at 1:250 dilution. Slides were washed with PBS for
5min, mounted with vector shield (H1200 with DAPI) and left
to dry for 20min before microscopy. Fluorescence images were
captured on a Zeiss Z1 AxioObserver fluorescence microscope.
Three coverslips/wells were used for each test and 500 cells were
counted from each coverslip; and the experiment performed
twice. Differences in relative translocation were analyzed using
one-way ANOVA with Bonferroni post-test analysis.
Cytoselect Monocyte-Endothelium
Adhesion Assay
This was applied according to the manufacturer instruction and
referring to the work of Kapitsinou et al. (13). Briefly, human
brain microvessel EC (HbMEC) (1 × 105/per well) were added
applied to a 96-well plate. After 48 h, when the EC monolayer
was formed, they were treated with mCRP (1–100µg/ml) for 6 h.
After removing the medium, they were washed once with serum
free medium, and 200 µl of the monocyte suspension already
labeled with Leuko-Tracker added to each well and incubated for
90min. After removing the medium and a further three washes,
150 µl of 1X lysis buffer was added to each well containing cells.
Fluorescence was measured using a fluorescence plate reader
at 480 nm/520 nm. In these experiments we added nCRP since
possible effects on EC-monocyte interactions have not previously
been examined. However since published data clearly shows a
lack of inflammatory activity on macrophages (3, 14), we did not
include it within the other experimental protocols. Each test was
conducted in triplicate, repeated three times, and a representative
example is given. ∗p ≤ 0.05 using Wilcoxon matched pair test.
Platelet Aggregation Assay
Venous blood was taken from non-smoking (since smoking
is known to affect/increase platelet aggregation) (15), healthy
volunteers with informed consent (carried out with internal
ethical approval obtained through our local University ethical
committee). Monomeric C-reactive protein-induced platelet
activation was evaluated using the platelet aggregation assay, and
its coagulationwasmeasured by light-transmission aggregometry
(LTA) using platelet rich plasma (PRP). Blood was centrifuged
(20min, 150 g, 20◦C) to obtain PRP.
A total of 250 µL of PRP adjusted to 250 × 106
platelets/mL was incubated with 250 µL solution containing
mCRP (100µg/ml) or control buffer and small molecules.
Adenosine diphosphate (ADP) at 10µM was used as a
positive control. Antibodies were used at 1:100 dilution. The
following concentrations were used for the small molecules,
mCRP 100µg/mL + nicotine 0.93µM, mCRP 100µg/mL
+ acetylcholine 10µM and mCRP 100µg/mL + tacrine at
10µM. Each experiment was performed in triplicate. Results are
presented as the mean ± SD of maximum platelet aggregation
(%), from a representative example of three independent
experiments. ∗P ≤ 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 using ANOVA.
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CRP Purity Testing
In all of the experiments CRP treated with detoxi-gel columns
(CRPdt) containing immobilized polymyxin B was used, to
ensure the absence of pyrogens/endotoxin (AffinityPakTM detoxi-
GelTM column; Pierce, Rockford, IL) and removal was confirmed
using the Limulus assay. Sources were purchased free from
sodium azide.
Dot-Blot Assay
Incubation of mCRP With Small Molecules
mCRP was incubated for 2 h with tacrine (10µM), nicotine
(0.93µM) or acetylcholine (100µM) prior to binding assessment
on nitrocellulose described below.
Dissociation of nCRP to mCRP
The nCRP commercial sample was purchased from Yo protein
laboratories (Aachen, Germany). 250µL of mCRP was added
250µL of 10mM EDTA and 8M urea for chelation and the
mixture incubated at 37◦C for 2 h, with or without tacrine
(10µM), nicotine (0.93µM), or acetylcholine (100µM).
A grid was drawn on a piece of nitrocellulose membrane
using a pencil and indicating the region for the blots. Next,
using a narrow-mouth pipette tip, 2 µl of samples was placed
onto the nitrocellulose membrane at the center of the grid.
The penetration area was kept to a minimum by applying it
slowly. After drying, non-specific sites were blocked with 5%
BSA in TBS-T (0.5–1 h, RT). A 10 cm petri dish was used as
a reaction chamber, and samples were incubated with primary
anti-mCRP/nCRP antibodies [1:10] dissolved in BSA/TBS-T
for 30min at RT. After washing three times with TBS-T
(3 × 5min), samples were incubated with secondary anti-
mouse antibody conjugated with HRP (1:500 for 30min at
RT).
After washing, (TBS-T; 15min × 1 and 5min × 2), then
once with TBS (5min), membranes were incubated with ECL
reagent for 1min, covered with Saran-wrap (after removal of
excessive solution from the surface), and exposed using the G-
box/Image Lab software. All blots were performed in triplicate
and experiments were repeated three times with a representative
example being shown.
Surface Plasmon Resonance Testing
Surface plasmon resonance (SPR) was used to assess the
binding of mCRP to nicotine, acetylcholine, tacrine and 3H12
polyclonal antibody. Monomeric CRP was first buffer exchanged
using a 0.5ml ZebaTM spin column (Thermo) which was
pre-equilibrated in PBS. mCRP was then incubated with a
1:2 ratio of NHS-Peg4-Biotin (Thermo) for 30min at room
temperature before purifying the free biotin with another ZebaTM
spin column in PBS. SPR was performed on a Biacore T200
(GE life sciences) and a streptavidin coated SA chip. The
instrument was equilibrated in Biacore buffer, 10mM HEPES
buffer pH 7.4 with 0.05% tween 20 and the SA chip was
washed with 10mM EDTA and 50mM NaOH prior to loading
with biotinylated mCRP. For the antibody binding test the
chip was loaded with ∼100 response units of mCRP. For
the small molecule tests the chip was loaded to a maximum
loading of ∼3,500 response units of biotinylated mCRP.
Analytes, either antibody at 1:100 dilution, 1mM nicotine,
1mM acetylcholine, or 10µM tacrine diluted in Biacore buffer
were injected at 30 µl/min over the mCRP surface and the
response monitored in real time. The results are shown as a
subtracted response where flow cell 1 was used as a reference
with no mCRP added which was subsequently subtracted from
the data.
Statistical Analyses
Data are presented as the mean± SD of individual representative
experiments carried out in triplicate. Statistical analysis was
performed using GraphPad Prism software version 7.0 for
Windows (GraphPad Software). The values were compared using
paired Student’s t-test, non-parametricWilcoxon test, or one-way
ANOVA with Bonferroni post-test analysis. ∗P ≤ 0.05; ∗∗P <
0.01; ∗∗∗P < 0.001.
RESULTS
mCRP Modulated TNF-α, IL-6, and IL-10
Expression in U937-Derived Macrophages
To determine the effect of mCRP on the expression of
inflammatory mediators, U937-derived macrophages were
exposed for 24 h to 100µg/ml mCRP and secreted protein levels
of TNF-α, IL-6, and IL-10 in the supernatant were quantified
using ELISA. As shown in Figure 1, mCRP significantly increased
the secretion of pro-inflammatory cytokines including TNF-α
(P < 0.05, Figure 1A) and IL-6 (P < 0.01, Figure 1B), exerting
a similar response to LPS. Surprisingly, mCRP significantly
decreased the levels of anti-inflammatory cytokine IL-10 by
25% (derived from our included representative experiment and
similarly decreased in repeated tests; P < 0.05, Figure 1C),
opposite to LPS which augmented the production of IL-10 by
2.2-fold (P < 0.001, Figure 1C).
We then investigated whether the small molecules
(acetylcholine, nicotine, tacrine) and anti-mCRP antibodies
(3H12 and 8C10) would affect macrophage cytokine profiles
induced by mCRP. Pre-treatment with acetylcholine, nicotine,
tacrine and anti-mCRP antibody 3H12 significantly inhibited
TNF-α production induced by mCRP, with the strongest
inhibition by acetylcholine (63.8% reduction), followed by
nicotine (52.6% reduction), 3H12 (31.8% reduction), and tacrine
(25.9% reduction) (derived from our included representative
experiment and similarly decreased in repeated tests; ANOVA,
P < 0.05, Figure 1A). Both acetylcholine and nicotine also
significantly decreased IL-6 levels induced by mCRP (P
< 0.05, Figure 1B). In addition, acetylcholine and 3H12
tended to restore the mCRP repressed IL-10 levels back to
normal (P < 0.05, Figure 1C). Small molecules alone did
not significantly increase macrophage cytokine expression
(values for TNF-α shown in Figure 1D). A small increase in
TNF-α was seen in the presence of 3H12/8C10 alone (in the
absence of mCRP) and this was probably due to a residual
low concentration of endotoxin found in the supernatant. To
confirm receptor interaction of mCRP on the cell surface of
macrophages we pre-incubated U937 with a pharmacological
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FIGURE 1 | The effect of mCRP on macrophage cytokine production. The differentiated U937 macrophages were pre-treated with acetylcholine (10µM), nicotine
(0.93µM), tacrine (5µM), anti-mCRP antibodies 3H12 (1:10) or 8C10 (1:10) for 2 h, followed by stimulated with mCRP (100µg/mL) for an additional 24 h. The
production of TNF-α (A), IL-6 (B), and IL-10 (C) in the supernatant was quantified using ELISA kits (R&D System). The stimulation with LPS (10 ng/mL) for 24 h was
used as the positive control for macrophage cytokine production. (D) Shows that treatment with small molecules alone, nicotinic acid receptor antagonist
methyllycaconitine (10µM) or CD16/32/64 to FC-È receptors (1:100) did not affect cytokine (TNF-α) production in U937 cells, although there was a marginal increase
in TNF-α in the presence of the mCRP antibodies probably due to residual contamination of low levels of LPS. When cells were pre-treated with CD16/32/64 to FC-È
receptors (1:100) for 2 h, complete abrogation of mCRP-induced TNF-α production was shown (E), whilst pre-incubation with the nicotinic acid receptor antagonist
methyllycaconitine (10µM) for 2 h in the presence of either acetylcholine or nicotine did not reverse the anti-inflammatory capacity (F). Results are presented as the
mean ± SD from a representative example of three independent experiments. *P ≤ 0.05; **P < 0.01; ***P < 0.001 using one-way ANOVA with Bonferroni post-test
analysis.
antagonist of nicotinic α7 receptor (methyllycaconitine;
10µM) or blocking antibodies CD16/32/64 to FC-È receptors
(1:100) for 2 h. A combination of antibodies CD16/32/64
was able to completely abrogate mCRP-induced TNF-α
production (P < 0.01, Figure 1E), whilst pre-incubation with
the nicotinic receptor antagonist methyllycaconitine (10µM
shown and 1–100µM tested) for 2 h in the presence of nicotine
did not reverse the anti-inflammatory effects suggesting a
pathway not working through the nicotinic receptor signaling
(Figure 1F). Acetylcholine, nicotine and methyllycaconitine
cytotoxicity studies are included as Supplementary Figure 1,
and no cytotoxicity was observed at any of the concentrations
used.
mCRP Induced the Phosphorylation of MAPK and
Activation of NF-κB in Cultured Macrophages
Differentiated U937 macrophages were pre-treated with
acetylcholine (100µM, lane 4; 10µM, lane 5) or nicotine
(0.93µM, lane 6) for 2 h, followed by stimulation with
mCRP (100µg/mL, lanes 3–6) for an additional 8min
(Figure 2A). Since tacrine was not effective in blocking
macrophage-induced inflammation (Figure 1) we did not
include it in these signaling experiments. The first lane
was loaded with the extract from untreated macrophages
as control. The cultured macrophages treated with LPS
(10 ng/mL) for 8min were used as a positive control (lane
2). Results show that acetylcholine was effective in blocking
phosphorylation of ERK1/2, NF-κB, and JNK1/2 but not p-38
MAP kinase. Nicotine similarly inhibited phosphorylation of
ERK1/2 JNK1/2 and NF-κB but not p38 signaling molecules.
Figures 2B–E shows densitometric analysis of immunoblot
quantification. Interestingly, acetylcholine alone increased NF-
κB phosphorylation as well as that of p-38 MAP kinase, whilst
increased p-38 phosphorylation was also seen after addition of
nicotine. No change in the expression of “total” proteins was
seen.
To confirm activation of NF-κB, we performed
immunofluorescent staining on cultured U937 macrophages
exposed to mCRP (100µg/ml; 1 h) or LPS as a positive control
(10 ng/ml). Nuclear translocation of NF-κB was clearly seen in
LPS-treated cells (∼63% of cells; iii) and also mCRP treated
U937 (∼30%; ii) but not in control untreated cells (<1%; i)
as shown in Figures 2F,G (P < 0.05 from a representative
experiment, which was repeated giving similar results). None
Frontiers in Immunology | www.frontiersin.org 5 September 2018 | Volume 9 | Article 2124
Slevin et al. Acetylcholine Inhibits mCRP-Induced Inflammation
FIGURE 2 | The expression of selected phospho-proteins by macrophages. 2 × 106 (U937 cells) were differentiated in one well of a 6-well plate. After 72 h, when the
macrophage monolayer had formed, they were treated with various concentrations of acetylcholine (10, 100µM) or nicotine (0.93µM) with or without mCRP
(100µg/ml) for 8min. After removing the medium, they were washed twice with ice-cold PBS, followed by addition of 200 µl of 1X lysis Buffer to each well. Lane 1,
control; Lane 2, LPS; Lane 3, mCRP; Lane 4, acetylcholine (10µM) + mCRP; Lane 5, acetylcholine (100µM) + mCRP; Lane 6, nicotine + mCRP; Lane 7,
acetylcholine alone (100µM); Lane 8, acetylcholine alone (10µM); Lane 9, nicotine alone. (A) Expressions of selected proteins. (B) Bar chart shows phospho-ERK1/2
expression. (C) Bar chart shows phospho-JNK expression. (D) Bar chart shows phospho-p38 expression. (E) Bar chart shows phospho-NFκb expression. (F) Shows
immunofluorescent demonstration of nuclear translocation of NFκb FITC green with DAB-blue positively stained nuclei (I, negative control; ii, mCRP treated for 1 h; iii,
LPS positive control; iv, acetylcholine; v, acetylcholine + mCRP; vi, nicotine; vii, nicotine + mCRP; viii, tacrine; ix, tacrine + mCRP), and (G) is a representative bar
chart showing the percentage of cells showing nuclear translocation from 500 counted cells/coverslip. Pre-incubation with nicotine (0.93µM; 1 h) significantly reduced
NFκb translocation. Each test was carried out in triplicate and the experiments conducted twice. A representative example is given here. **P < 0.01; ***P < 0.001
using one-way ANOVA with Bonferroni post-test analysis.
of the small molecules alone had any effect on translocation
(iv, vi, and viii), however pre-incubation of cells with nicotine
(0.93µM; 1 h) significantly reduced the translocation of NF-κB
(p < 0.05; from 30 to 18% in our presented experiment which
was performed twice giving similar results). This data confirmed
mCRP-induced activation of the NF-κB signaling pathway with
gene transcriptional involvement.
mCRP-Induced EC-Monocyte Adhesion Tends to Be
Inhibited by 8C10 Antibody
Monocyte adherence to the endothelium is a strong indicator
of abnormal activity/activation and potential for inflammatory
signaling associated with vascular damage that may ultimately
lead to atherosclerosis. mCRP significantly increased EC
adhesion to monocytes in a dose dependent manner whilst
native CRP (nCRP) had no significant effect (Figure 3A).
Acetylcholine and nicotine alone significantly promoted EC
adhesion to monocytes (P < 0.05), however, in the presence
of mCRP, they tended to antagonize mCRP-mediated adhesion
of EC to monocytes (non-significant; Figure 3B). mCRP-
induced EC-monocyte adhesion tended to be inhibited by
8C10 particularly at 1:10 dilution (Figure 3C). Figure 3D
shows that mCRP specific antibody 3H12 had a weak
but non-significant inhibitory effect at 1:10 dilution only.
Each test was conducted in triplicate and statistical analysis
performed using the Wilcoxon matched pair test. Experiments
were repeated three times and a representative example is
given.
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FIGURE 3 | The effect of mCRP on endothelial cell adhesion to U937. After treating with mCRP for 6 h (10–100µg/ml), monolayer HBmEC were incubated with U937
cells labeled with Leuko-Tracker for 60min. Fluorescence of the control wells containing EC and U937 without any treatment were arbitrarily set as 1. (A) mCRP
significantly increased EC adhesion to U937 in a dose dependent manner, however nCRP had no significant effect. (B) Acetylcholine (10µM), and nicotine (0.93µM),
alone significantly promoted EC adhesion to U937, however, in the presence of mCRP, they antagonized mCRP-mediated adhesion of EC to U937 (non-significant).
(C) Monomeric C-reactive protein specific antibody 8C10 also inhibited mCRP-mediated EC adhesion to U937. (D) mCRP specific antibody 3H12 reduced the
aggregation but to a lesser extent than 8C10 (non-significant). Each test was conducted in triplicate, repeated three times, and a representative example is given.
*p ≤ 0.05, **p < 0.01 using Wilcoxon matched pair test. Using ANOVA, no statistical differences were found in the inhibition of mCRP-driven EC adhesion to U937
cells.
Small Molecules and Antibodies Effectively Blocked
Platelet Aggregation
The measurement of platelet aggregation is a strong
indicator of the potential for thrombus or clot formation
in acute coronary syndromes. Platelet aggregation analysis
revealed that mCRP (100µg/ml; 5min), induced platelet
aggregation (40–50%), as seen in Figure 4A. Monomeric
C-reactive protein-induced platelet aggregation was blocked
in the presence of the anti-mCRP antibody (8C10), and
partially prevented by anti-mCRP antibody (3H12). All
three small molecules almost completely inhibited mCRP-
induced platelet aggregation (P < 0.05), but did not
block aggregation induced by ADP (10µM; Figure 4B).
Monomeric C-reactive protein-induced aggregation of
platelets was independently tested using a second healthy
donor and similar levels of aggregation were produced
(Supplementary Figure 2).
Antibody and Protein Binding Studies
Indicated No Direct Interaction Between
Small Molecules and mCRP
Here, we used dot blotting with our specific mCRP antibody
3H12 in order to examine possible interactions that would
affect surface structure change/binding. No significant change
in specific antibody binding was found between the mCRP
control sample and mCRP samples pre-treated for either 2 or
4 h with any of the three small molecules (Figure 5A). After
incubation of nCRP with urea at 37◦C, dot blots obtained
following incubation with mCRP antibody 3H12 indicated that
urea mediated dissociation of nCRP to mCRP was not affected by
acetylcholine, tacrine or nicotine (Figure 5B).
SPR binding analysis was used to identify any adsorption of
material on to themCRP-coated electrodes. Results indicated that
under these conditions there was no observable direct interaction
of any of the small molecules to biotinylated mCRP. The 3H12
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FIGURE 4 | Platelet aggregation assay: (A) Platelet aggregation/ coagulation was measured by light-transmission aggregometry (LTA) using PRP derived from
volunteers fresh whole blood. Monomeric C-reactive protein (100µg/ml)-induced platelet aggregation was blocked by anti-mCRP antibody (8C10) and partially
inhibited by anti-mCRP (3H12). Acetylcholine (10µM), nicotine (0.93µM), and tacrine (5µM), almost completely inhibited mCRP-induced platelet aggregation (P <
0.05), whilst having no effect either alone or on ADP-induced platelet aggregation (B). The experiments were each performed in triplicate. Results are presented as the
mean ± SD from a representative example of three independent experiments. *P ≤ 0.05; **P < 0.01; using one-way ANOVA with Bonferroni post-test analysis.
FIGURE 5 | Dot-blot and cell binding assays: (A) After Incubation of mCRP with and without tacrine, nicotine, and acetylcholine for 4 h, dot blotting with 3H12
showed no significant specific antibody binding. (B) Following incubation of nCRP with urea at 37◦C dot blotting using 3H12 to bind to the mCRP indicated that
dissociation of nCRP to mCRP was not affected by the presence of any of the three small molecules. (C) The results of SPR showed that there was no observable
interaction of the small molecules to biotinylated mCRP. The 3H12 antibody exhibited a strong response with a slow off-rate (kd) of ∼7.8 × 10−4 s−1. Experiments
were performed in duplicate and repeated three times. Results are presented as the mean ± SD from a representative example. No significant differences were found
using one-way ANOVA with Bonferroni post-test analysis.
antibody, however, exhibited a strong response with a slow off-
rate (kd) of ∼7.8 × 10−4 s−1 (Figure 5C). For each experiment,
duplicates of each sample were made, and three repeats of each
experiment were carried out with a representative example being
shown here.
DISCUSSION
mCRP is involved in significant perpetuation of tissue associated
inflammation, potentially associating it to thrombosis in
atherosclerosis (14), neurological degradation and dementia
(16), macular degeneration (17), and sepsis (18). Therefore,
antagonists of either, native CRP breakdown and dissociation
into mCRP, or small molecules that would inhibit mCRP binding
and activation via the cell membrane phosphocholine docking
site, could prove useful as future therapeutic agents.
Apart from our characterized antibodies (3H12 and 8C10;
8C10 having been previously shown by ourselves to block mCRP-
induced cell signaling through p-ERK1/2 and angiogenesis
in bovine aortic EC); (16), we investigated the potential of
acetylcholine, nicotine and tacrine to modulate mCRP-induced
inflammation. Acetylcholine is very similar in structure to
phosphocholine. Work by Nazarov et al. (19) indicates that
CRP could bind to acetylcholine, as evidenced, by CRP-based
inhibition of breakdown of this molecule and subsequent
influence on cardiovascular systemic inflammation. In order to
gain some insight into potential CRP/acetylcholine interactions
and how this compares to binding at known cholinergic
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receptors/enzymes; we also chose to examine the effects of
nicotine – the putative agonist at nicotinic receptors and tacrine,
a therapeutically useful inhibitor of acetylcholinesterase.
The induction of inflammation in U937-derived macrophages
in vitro is a reliable indication of the activity of mCRP, and
increases in IL-6 and TNF-α are attributed to detrimental
tissue-related complications (20). Here we showed that both
acetylcholine and nicotine were able to attenuate, significantly,
both TNF-α and IL-6 activity, whilst neither tacrine nor the
targeting antibodies were effective. In addition, a small decrease
in production of the anti-inflammatory cytokine IL-10 was
noticed, in the presence of mCRP, but this tended to return to
basal levels in the presence of acetylcholine or 3H12 antibodies.
A reduction in anti-inflammatory cytokines elicited by mCRP
could potentially alter the vascular micro-environment leading
to enhanced inflammation and hence molecules that could block
this effect systemically could have some therapeutic interest (21).
Il-1βwas also tested and substantially increased in the presence of
mCRP, however, neither the antibodies nor the small molecules
used showed any significant inhibition of cytokine expression
(data not shown).
Previous work has demonstrated mCRP induced production
of IL-6 and TNF-α in U937macrophages via Fc-gamma receptor-
associated signaling and that co-incubation with oxidized LDL
antagonized this inflammatory response (3). This pair of
cytokines are linked in systemic inflammation/acute and chronic
infection and are associated with increased risk of atherosclerosis
and thrombosis and therefore blocking their production with a
novel inhibitor such as acetylcholine could protect highly at risk
individuals (22).
To confirm that macrophage cell signaling was perturbed,
we carried out Western blotting experiments. Previously, Li et
al. (23) showed that EC stimulation with mCRP induced MAP
kinase signaling and p-38, NF-κB, associated with increase in IL-
6 cytokine expression. Only one published study investigating
the effects of mCRP on macrophage signaling was carried out
previously by Eisenhardt et al. (24) who performed proteomic
analysis on THP-1 macrophages, but did not identify any critical
signaling intermediates associated with pro-inflammatory gene
expression.We pre-incubatedmacrophages with acetylcholine or
nicotine (since they produced a strong inhibitory inflammatory
response in the presence of mCRP) and observed a reduction
in p-ERK1/2 by both, and NF-κB phosphorylation in the
presence of both acetylcholine and nicotine (p-JNK was
weakly inhibited whilst AKT/p-p38 were not affected—AKT
not shown). mCRP also caused nuclear translocation of NF-
κB (by immunofluorescent analysis, for which the data are
derived from only duplicate experiments)-a process associated
with phosphorylation and degradation of IÎBα normally allowing
translocation of NFkB into the nucleus where it regulates gene
transcription).
The phosphorylation of NF-κB by acetylcholine when applied
alone is difficult to explain but this was previously reported
following incubation with a bronchial epithelial cell line, and
linked to increased IL-8 production, although the mechanism
responsible for this is not clearly understood (25). Oenema et al.
showed stimulation of IÎB in smooth muscle cells through the
muscarinic receptors indicating a possible signaling mechanism
for this surprising finding (26).
Previous work has shown that both p-38 and NF-κB are
required for IL-6/TNF-α processing in multiple cell types (27),
and hence our work provides an indication that, particularly,
acetylcholine, may block mCRP binding and signaling pathways
associated with its powerful pro-inflammatory action.
We assessed whether there was a direct interaction between
mCRP/nCRP and small molecules to indicate if direct binding
possibly leading to structural modification, may be responsible
for imparting biological inhibition. Dot blots performed on
nitrocellulose bound with specific mCRP antibodies showed no
ability of the small molecules to block binding directly to the
antibody, nor to inhibit native CRP dissociation in the presence
of urea. Similarly SPR could not show any direct interaction apart
from the antibody (which we used as a positive control), thus
indicating the interaction of these substances with mCRP may
be at themembrane-phosphotidylcholine binding site rather than
specific binding to the CRP which should be the subject of further
investigation.
To further investigate the effects on macrophage activation
and the relationship with EC adhesion, we conducted the
Cytoselect monocyte-EC adhesion assay. Previous work has
shown an important role for mCRP in stimulation of neutrophil
attachment to human coronary artery EC [HCAEC; (28)],
whilst Khreiss et al. (29), showed mCRP-induced HCAEC
through enhanced MCP-1 and IL-8 secretion with concomitant
phospho-p-38 expression, although there is no specific literature
describing the link between EC and macrophages. Recently,
mCRP was shown to activate angiogenesis and trigger F3 gene
transcription, upregulating tissue factor signaling (30). Here
we show that mCRP induced EC-monocyte adhesion and this
was notably inhibited in the presence of both nicotine and
acetylcholine (although not tacrine), and also, similarly using
our two targeting antibodies, although these trends were non-
significant. Inflammation and cell “stickiness” linked to mCRP
are known to encourage monocyte attachment to the vascular
cell wall for example at the early stages of atherosclerosis (31),
and later as a precipitant of thrombosis with platelet aggregation
involvement (32).
Regarding platelet aggregation, mCRP at 100µg/ml was
previously shown to cause CD62-platelet aggregation and
adhesion to fibrinogen (33). Using our standardized thrombotic
assay, we showed that mCRP (100µg/ml) significantly induced
thrombosis within 2min of application (∼39%). In the presence
of small molecules/antibodies, whilst the 3H12 was ineffective,
the 8C10 antibody and all three small molecules significantly
attenuated platelet aggregation, whilst the positive control
ADP was not blocked. Mollins et al. (32), partially explained
the mechanism of mCRP action through surface P-selectin
activation, CD63 exposure, and glycoprotein IIb-IIIa activation.
Although we are not sure of the characteristics of our small
molecules, the thrombotic pathway appears to be driven at least
partially through p-38 activation and at least acetylcholine was
able to block this pathway hence this could help to explain our
findings. Regarding the anti-mCRP antibodies, the 8C10 binds to
the N-terminal part of mCRP through aa 22–45 thereby covering
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the cholesterol binding site and probably explaining amechanism
for prevention of mCRP from entering lipid rafts (2). This may
explain its greater effectiveness when compared with the 3H12
antibody which binds the C-terminal octapeptide aa 198–206.
Since this epitope becomes hidden after mCRP enters a lipid zone
e.g., on the surface of a cell membrane or lipid rafts of platelets,
mCRP may have bound to the platelets prior to an effective
influence of the antibodies or small molecules since there was no
pre-incubation phase in this experiment.
We confirm here that small molecules like acetylcholine
and nicotine could potentially be developed or optimized as
protectors in cardiovascular and other inflammatory debilitating
conditions. Nonetheless acetylcholine administration may have
considerable severe side effects when administered systemically,
(e.g., inhibition of other normal CNS functions by blocking
serotonin function) leading to enhanced anxiety and depression
(34). In addition, since the normal half-life of acetylcholine
in the blood is 1–2min, treatment requiring prolonged action
systemically would require additional anticholinesterase therapy,
and in fact, tacrine, is an example of a drug previously tested for
management of Alzheimer’s within the USA (35).
It is worthy of note that whilst several years ago, there
was some controversy over the existence of mCRP in vivo,
and identification of the active rmCRP; an intermediate form
produced on contact of the native protein with cell membranes
and liposomes (36, 37). More recent work from Thiele et
al. (4) and others, demonstrated manipulation of CRP using
a specific phosphocholine inhibitor (1-6-bis(phosphocholine)-
hexane), in vivo. They showed the existence of mCRP in tissue
and pharmacologically successfully blocked this dissociation
directly at the cell surface, thereby validating our studies here
and indicating a possible novel therapeutic strategy to abrogate
inflammatory disease.
In conclusion, orphan, off target molecules such as
acetylcholine or more specific small molecules, of similar
structure may have potential for blocking the pro-inflammatory
effects of CRP.
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Supplementary Figure 1 | Shows trypan blue cytotoxicity screening and no
significant cell death or loss of viability after 24 h in the presence of the following
concentrations of the small molecules /nicotinic acid receptor inhibitors used
within this study (acetylcholine-0–500µM; nicotine-0–150 ng/ml;
methyllycaconitine citrate-0–200µM). Each experiment was performed three
times in triplicate and a representative example is shown here.
Supplementary Figure 2 | Results for a second donor for the platelet
aggregation assay showing a similar pattern of results for mCRP and the effects of
the small molecules on aggregation. Anti-mCRP antibody 8C10 blocked
effectively the aggregation of platelets by mCRP whilst 3H12 only partially
abrogated the effects (P < 0.05). Acetylcholine (10µM), nicotine (0.93µM), and
tacrine (5µM), all significantly inhibited mCRP-induced platelet aggregation.
Results are presented as the mean ± SD from a representative example (different
donor) of three independent experiments. ∗P ≤ 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001
using one-way ANOVA with Bonferroni post-test analysis.
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